RBCC to Expand Market for 'Underused' Addiction Treatment With New Technology

By Business Wire,  June 11, 2014, 05:00:00 AM EDT

MIRAMAR BEACH, Fla.--(BUSINESS WIRE)-- Rainbow Coral Corp. (OTCBB:RBCC) received a boost recently when researchers reported that a medication that could help tens of thousands of alcoholics quit drinking are underused.

According to the high-profile findings, which were reported by the New York Times, the prescription drug Naltrexone can help reduce cravings for alcohol by fine-tuning the brain's chemical rewards system. A lack of awareness among doctors as well as other factors have resulted in the drug's being underused, researchers reported earlier this month. Because the Affordable Care Act requires insurers to provide coverage for substance abuse treatments and services, many addiction specialists expect to see increases this year in the number of people seeking medical help for alcoholism.

That's good news for RBCC. The company formed a joint venture with TheraKine, Ltd., to deliver a new injectable, sustained-release technology poised to vastly improve patients' use of Naltrexone. Phase I of the joint venture's research established excellent compatibility between the drug and TheraKine's hydrophobic injection matrix, as well as a highly promising release profile. Phase II focused on micronization of the technology as well as extension of its sustained release time.

This summer, RBCC will focus on demonstrating the new technology's readiness for market with the number of prescriptions for alcoholism predicted to rise.

RBCC's biotech division, Rainbow BioSciences, is working with partners such as TheraKine to capitalize on the incredible growth of the global drug delivery market by delivering new medical and research technology innovations in order to compete alongside companies such as Bristol Myers Squibb Co. (NYSE:BMY), Biogen Idec Inc. (NASDAQ:BIIB), Abbott Laboratories (NYSE:ABT) and Valeant Pharmaceuticals International (NYSE:VRX).

For more information on RBCC's other biotech initiatives, please visit www.rainbowbiosciences.com.

About Rainbow Biosciences

Rainbow Biosciences, LLC, is a wholly owned subsidiary of Rainbow Coral Corp. (OTCBB:RBCC). The Company continually seeks out new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations. For more information on our growth-oriented business initiatives, please visit www.RainbowBioSciences.com.

Notice Regarding Forward-Looking Statements

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipate" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone's past success, either financial or strategic, is no guarantee of future success. This news release speaks as of the date first set forth above and the Company assumes no responsibility to update the information included herein for events occurring after the date hereof.

Source: Rainbow Coral Corp.

This article appears in: News Headlines

Referenced Stocks: ABT, BIIB, BMY, RBCC , VRX

Latest News Video

Most Active by Volume

Company Last Sale Change Net / %
BAC $ 16.295 0.04 ▼ 0.21%
FB $ 74.8145 1.15 ▼ 1.51%
TWTR $ 47.92 0.25 ▼ 0.52%
SIRI $ 3.59 0.03 ▲ 0.84%
YHOO $ 38.007 0.22 ▲ 0.57%
AAPL $ 100.7331 0.16 ▼ 0.15%
HAL $ 68.255 1.56 ▼ 2.23%
PFE $ 29.455 0.25 ▲ 0.84%

As of 8/27/2014, 10:40 AM